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Cancer side population (SP) cells with cancer stem cell-like properties are thought to be
responsible for lung cancer chemotherapy resistance and currently no drug can efﬁciently
target them. Breast cancer resistance protein (BRCP/ABCG2) is a major drug transporter in
protecting lung cancer SP cells from cytotoxic agents.We showed that a low concentration
of ethanol, which inhibits manymembrane proteins, inhibits ABCG2 in lung cancer SP cells.
Furthermore, cytotoxic cisplatin (DDP) in 5% (vol/vol) ethanol kills SP plus non-SP cancer
cells better than either treatment alone in eradicating chemoresistant lung tumors. We
found that 5% ethanol did not reduce ABCG2 protein levels, but signiﬁcantly reduced
ABCG2 protein function by a Hoechst 33342 extrusion assay, an ATPase activity assay, and
transmission electron microscopy. Further, DDP in 5% ethanol (5% ethanol–DDP) induced
apoptosis of the SP plus non-SP cancer cells both in vitro and in vivo. In DDP-resistant
A549/DDP lung tumor-bearing Balb/C nude mice, intratumoral injection of 5% ethanol–
DDP regressed tumors and signiﬁcantly improved survivals compared with 5% ethanol,
DDP alone, or control. Intratumoral injection of 5% ethanol–DDP helped eradicate tumors
in 30% (3/10) of the mice after 4 weeks treatment. By killing SP and non-SP cancer cells,
5% ethanol–DDP could eradicate DDP-resistant lung tumor and extend survival, providing
a novel way to improve chemoresistant lung cancer survival for clinic.
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INTRODUCTION
Chemotherapy resistance, believedbymany tobemediatedby can-
cer stem-like cells, accounts for a majority of lung cancer deaths
(Dean et al., 2005; Eramo et al., 2010). The cancer stem cell (CSC)
theory states that tumors are organized in a hierarchical manner
similar to normal tissues, with a sub-population of tumorigenic
stem-like cells that are chemoresistant and generate relapse (Dean
et al., 2005). Recent observations found that CSC populations are
ﬂexible and in dynamic states as cancer cells can also dedifferen-
tiate into CSCs (Gerlinger et al., 2012; Visvader and Lindeman,
2012).
Side population (SP) cells with CSC-like properties were
ﬁrst identiﬁed in leukemia and subsequently isolated from solid
tumors, including breast, brain, lung, liver, prostate, colon, pan-
creatic, and head and neck cancers (Bonnet andDick, 1997; Eramo
et al., 2008; Charafe-Jauffret et al., 2009; Singh et al., 2010).
Side population cells express high levels of breast cancer
resistance protein (BRCP/ABCG2) which functions as an ATP-
dependent membrane transporter. ABCG2 efﬁciently efﬂuxes a
variety of chemotherapy drugs or drug conjugates in SP cells and
is believed to be the main basis of chemotherapy resistance (Singh
et al., 2010; Niu et al., 2012; Zhang et al., 2012).
We previously isolated SP cells from cisplatin (DDP)-resistant
human lung adenocarcinoma A549/DDP cells by ﬂuorescence
activated cell sorting (FACS) and demonstrated that they could
be used to screen ways to kill SP cells with CSC-like properties
(Niu et al., 2012).
Current investigated CSC-targeting agents including low
molecular weight heparin, metformin, dopamine receptor antag-
onist, mithramycin, salinomycin, sulforaphane, miR-34a and
other CSC-speciﬁc signaling pathway inhibitors such as molecules
affecting Wnt, EpCAM, Hedgehog, and Delta/Notch signaling
have been shown effects (Alison et al., 2011; Liu et al., 2011; Li et al.,
2012; Niu et al., 2012; Sachlos et al., 2012; Vermeulen et al., 2012;
Zhang et al., 2012). However, most of them have only attenuated
rather than eradicated solid tumors and could not extend survival
in vivo. The reason could be the CSCs population is ﬂuid and
current CSCs-targeting agents have been designed only to target
ﬁxed population (Vermeulen et al., 2012; Visvader and Lindeman,
2012).
Recently, liposomal cisplatin has been formulated and tested
thoroughly in preclinical and clinical trials. Experiments in ani-
mals showed that liposomal formulation is less toxic than cisplatin.
However it did not enhance clinical efﬁcacy (Stathopoulos, 2010;
Zisman et al., 2011).
We hypothesize a low concentration of ethanol, which inhibits
many membrane proteins, might be able to inhibit ABCG2 in
lung SP cells and make them less efﬁcient at pumping out DDP
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(Lucero et al., 1997; He et al., 2006). Thus, cytotoxic DDP in the
low concentration of ethanol may kill lung SP plus non-SP cancer
cells and eradicate chemoresistant lung tumor. If so, image-guided
intratumoral injection of it might provide a novel way to improve
chemoresistant lung cancer survival. Therefore, this study investi-
gates whether 5% ethanol could inhibit ABCG2 and DDP in 5%
ethanol could kill lung SP plus non-SP cancer cells in vitro as well
as its effects on DDP-resistant tumors in vivo.
RESULTS
SIDE POPULATION SORTING
A SP of 10–18% cells existed in A549/DDP cells. The purity of SP
cells was >95% (average 97%) and sorted SP cells were used for
further experiments.
5% ETHANOL DID NOT AFFECT ABCG2 mRNA EXPRESSION IN SP CELLS
AND TUMOR XENOGRAFTS CELLS WITH RT-PCR
Relative mRNA level of SP cells treated with 5% ethanol to control
was 1.12 ± 0.09. Similarly, relative mRNA level of 5% ethanol-
treated tumor xenografts cells to control was 1.08 ± 0.07. No
signiﬁcant change was found in ABCG2 mRNA level after 5%
ethanol treatment both in SP cells and in xenografts tumor cells
(Figure 1A).
5% ETHANOL DID NOT CHANGE ABCG2 PROTEIN EXPRESSIONS IN
LUNG SP CELLS AND TUMOR TISSUES BY WESTERN BLOTS
ABCG2 protein expressions in 5% ethanol-treated SP cells and
tumor tissues had no signiﬁcant changes compared with ABCG2
expressions in each corresponding control. The values of ABCG2
FIGURE 1 | (A) ABCG2 mRNA levels in 5% ethanol-treated lung SP cells and
tumor cells relevant to controls. Quantitative real time RT-PCR showed that
the expressions of ABCG2 mRNA were not signiﬁcantly changed in SP cells
and tumor cells by 5% ethanol treatment compared with its expressions in
controls. (B)Western blots analysis of ABCG2 expressions in SP cells and
tumor tissues treated with 5% ethanol and control. ABCG2 protein
expressions in 5% ethanol-treated SP cells and tumor tissues had no
signiﬁcant changes compared with ABCG2 expression in each corresponding
control. (C) Alteration of ABCG2 protein activity by 5% ethanol. Compared
with the side population of 17.45% ± 2.6% in control cells, 5% ethanol
signiﬁcantly decreased the side population by 95.2% (0.83% ± 0.2%).
(D) 5% ethanol reduced ATPase activity in lung SP cells by ATPase activity
assays. Compared with the value of ATPase activity in control SP cells, a
signiﬁcant decrease by 96.6% was observed in the ATPase activity of 5%
ethanol-treated SP cells. (E) Surface morphology of SP cells treated with 5%
ethanol and control by TEM. (a)TEM image of control SP cells (×4000).
(b)TEM image of control SP cells (×10000). (c)TEM image of 5%
ethanol-treated SP cells (×4000). Notable shortened microvilli and diminution
in their number were showed. The shortened microvilli are indicated by
arrows. (d)TEM image of 5% ethanol-treated SP cells (×10000).
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band density to β-actin band density in control SP cells and
5% ethanol-treated SP cells were 1.06 ± 0.21 vs. 1.10 ± 0.19,
p > 0.05. The values of ABCG2 band density to β-actin
band density in control tumor tissues and 5% ethanol-treated
tumor tissues were 1.09 ± 0.16 vs. 1.12 ± 0.20, p > 0.05.
(Figure 1B).
ALTERATION OF ABCG2 PUMP ACTIVITY BY 5% ETHANOL
Compared with the sorted SP of 17.45% ± 2.6% by ABCG2 pump
in control cells, 5% ethanol signiﬁcantly decreased the sorted SP
by 95.2% (0.83% ± 0.2%; Figure 1C).
ATPase ACTIVITY ASSAYS
Compared with ATPase activity in control SP cells (6.842 ± 0.462
nmol Pi/mg protein/min), 5% ethanol signiﬁcantly decreased
ATPase activity of SP cells to 0.231 ± 0.091 nmol pi/mg pro-
tein.min, by 96.6% (Figure 1D).
TRANSMISSION ELECTRON MICROSCOPY STUDIES
Three signiﬁcant changes in SP cells after 5% ethanol treatment
were observedwith transmission electronmicroscope (Figure 1E).
Firstly, the microvilli of SP cells treated by 5% ethanol were
shortened and greatly reduced in number, which reduced the
cell membrane surface, thus reducing the number of functional
ABCG2 pump in reduced cell membrane surface. Secondly, the
mitochondrial, which generates most of ATP as a membrane-
enclosed organelle, became swelling and its cristae disappeared.
This could make the ABCG2 pump, which is an ATPase, par-
tially inactivated or even totally. Thirdly, the rough endoplasmic
reticulum, which is involved in the synthesis of proteins, became
swelling and ribosomes fell off from its surface. These could cause
disfunction in synthesis of proteins including ABCG2.
5% ETHANOL–DDP INDUCED SP CELLS AND NON-SP CELLS
APOPTOSIS BY FACS
The SP cells apoptosis rates in different treatment groups
were: 0.76% ± 0.1% for control, 3.03% ± 0.5% for DDP,
1.86% ± 0.2% for 5% ethanol, and 93.32% ± 7.63% for 5%
ethanol–DDP (Figure 2A). Compared with control, 5% ethanol–
DDP induced SP cells apoptosis signiﬁcantly (93.32% ± 7.63%
vs. 0.76% ± 0.1%, p < 0.05; Figure 2B). In non-SP cells,
both 5% ethanol–DDP and DDP induced apoptosis signiﬁcantly
(98.32% ± 0.8% for 5% ethanol–DDP vs. 4.5% ± 0.5% for con-
trol, p < 0.05; 60.16% ± 6.8% for DDP vs. 4.5% ± 0.5% for
control, p < 0.05), but 5% ethanol did not (6.4% ± 0.5% for 5%
ethanol vs. 4.5% ± 0.5% for control, p > 0.05) compared with
control.
5% ETHANOL–DDP INDUCED TUMOR CELLS APOPTOSIS BY TUNEL
Compared with control, 5% ethanol–DDP increased apoptotic
cells as shown in Figure 3A. The rates of total apoptotic
cells were 60.11% ± 7.52% in the 5% ethanol–DDP-treated
tumor tissues and 5.32% ± 1.76% in the control tumor tis-
sues. 5% ethanol–DDP caused an 11.3-fold increase of apoptosis
(Figure 3A).
DDP-RESISTANT TUMOR XENOGRAFTS IN NUDE MICE WERE
COMPLETELY DESTROYED BY 5% ETHANOL–DDP TREATMENT
5% Ethanol–DDP could signiﬁcantly inhibit tumor growth com-
pared with tumor size of 3.68 ± 0.48 cm3 for control after 4 weeks’
treatment (0.11 ± 0.06 cm3 for 5% ethanol–DDP, p < 0.05).
Intratumoral injection of 5% ethanol–DDP to A549/DDP tumor-
bearing mice resulted in complete tumor regression in 3 of 10
mice (30%) and tumor growth arrest in the rest seven mice (70%)
after 4 weeks’ treatment. Average tumor volume in 5% ethanol–
DDP mice was signiﬁcantly reduced compared with DDP alone
(0.11±0.06 cm3 for 5%ethanol–DDPvs. 1.63±0.31 cm3forDDP,
p < 0.05) or 5% ethanol alone (0.11 ± 0.06 cm3 for 5% ethanol–
DDP vs. 3.81 ± 0.63 cm3for 5% ethanol, p < 0.05) or control
mice (0.11 ± 0.06 cm3 for 5% ethanol–DDP vs. 3.68 ± 0.48 cm3
for control, p < 0.05) after 4 weeks’ treatment. Although 5%
ethanol-treated mice have a trend toward increasing tumor size
after 3 weeks’ treatment, no signiﬁcantly difference was found
FIGURE 2 | (A) Apoptosis analysis of SP cells treated with 5% ethanol,
DDP, 5% ethanol–DDP, and control by FACS. (a) Apoptosis of control SP
cells. (b) Apoptosis of 5% ethanol-treated SP cells. (c) Apoptosis of
DDP-treated SP cells. (d) Apoptosis of 5% ethanol–DDP-treated SP cells.
(B) Apoptosis rate of treated SP cells. The most signiﬁcant apoptosis rate
was found in 5% ethanol–DDP-treated SP cells.
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FIGURE 3 | (A) Apoptosis analysis of 5% ethanol–DDP-treated tumor
tissues withTUNEL staining. (a) Control tumor tissue. (b) 5% ethanol–DDP
treated tumor tissue. Compared with control, 5% ethanol–DDP
signiﬁcantly increased tumor cell apoptosis rate (60.11% ± 7.52% vs.
5.32% ± 1.76%, p < 0.05). (B) DDP-resistant tumor size changes by
various treatments. 5% ethanol–DDP signiﬁcantly inhibited tumor growth
compared with control or DDP alone or 5% ethanol after 4 weeks’
treatment. E–D stands for ethanol–cisplatin. (C) Survival of A549/DDP
tumor-bearing mice in different groups. 5% ethanol–DDP treatment
signiﬁcantly improved estimated mean survival time compared with control
or DDP alone or 5% ethanol. E–D stands for ethanol–cisplatin.
between 5% ethanol-treated mice and control mice after 4 weeks’
treatment (3.81 ± 0.63 cm3 for 5% ethanol vs. 3.68 ± 0.48 cm3
for controls, p> 0.05; Figure 3B).
SURVIVALS OF TUMOR-BEARING NUDE MICE IN DIFFERENT GROUPS
5% Ethanol–DDP treatment could signiﬁcantly extend survival
and it produced the longest survival among all investigated groups
of mice. After 180 days’ observance, 80% (8 of 10 mice) of
5% ethanol–DDP-treated mice were still alive with 2 deaths for
non-tumor-related reasons, while all 10 control mice died before
Day 123. The estimated mean survival time of 5% ethanol–DDP
group mice (169.9 ± 6.5 days) was signiﬁcantly longer compared
with estimated mean survival time of DDP or control or 5%
ethanol alone groups (110.8 ± 5.1 days for DDP mice, p < 0.05;
90.6 ± 9.0 days for control mice, p < 0.05; 84.9 ± 4.1 days for
5% ethanol mice, p < 0.05). 5% ethanol alone treatment did
not signiﬁcantly change estimated mean survival time compared
with control (84.9 ± 4.1 days for 5% ethanol mice, p = 0.104;
Figure 3C).
DISCUSSION
In this study, we found that 5% ethanol could signiﬁcantly inhibit
ABCG2 protein function without affecting its mRNA and protein
expression in the lung SP cells. 5% ethanol signiﬁcantly decreased
ATPase activity of the lung SP cells by 96.6% with ATPase activity
assay and the ABCG2 pump activity by 95.2% with Hoechst 33342
extrusion studies, showing a signiﬁcant reduction of ABCG2
pump activity. The changes in microvilli, mitochondrial, and
rough endoplasmic reticulum of the lung SP cell ultrastructure
further conﬁrm ABCG2 pump function in cell membrane was
greatly reduced by 5% ethanol treatment.
Under the inhibition of ABCG2 function by 5% ethanol, cyto-
toxic DDP could stay in lung SP cells as well as non-SP cells and
thus efﬁciently kill them. Our results show thatDDP in 5%ethanol
(5% ethanol–DDP) could kill both lung SP cells plus non-SP cells
in vitro with FACS analysis and DDP-resistant tumor cells in vivo
with TUNEL assay. Intratumoral injection of 5% ethanol–DDP
could induce complete tumor regression in 30% of the mice by
killing lung SP cells plus non-SP cancer cells and signiﬁcantly
improved tumor-bearing mice survivals.
5% Ethanol–DDP could eradicate tumors by killing lung SP
cells plus non-SP cancer cells, presenting the strongest in vivo
effects among all the reported CSC-targeting agents in solid can-
cers (Niu et al., 2012; Sachlos et al., 2012; Vermeulen et al., 2012;
Visvader and Lindeman, 2012; Zhang et al., 2012; Okuda et al.,
2013). By contrast, other investigated anti-CSCs agents includ-
ing low molecular weight heparin, metformin, dopamine receptor
antagonist, mithramycin, salinomycin, sulforaphane, miR-34a,
and CSC-speciﬁc signaling pathway inhibitors have mostly atten-
uated rather than eradicated solid tumors in preclinical models by
targeting only ﬁxed population of CSC-like cells. And unharmed
cancer cells may dedifferentiate into CSC-like cells later. These
suggest that targeting both lung SP cells and non-SP cancer cells
by 5% ethanol–DDP is superior to other agents designed to target
ﬁxed population of CSC-like cells since cancer cells can also dedif-
ferentiate into CSC-like cells (Niu et al., 2012; Sachlos et al., 2012;
Vermeulen et al., 2012; Visvader and Lindeman, 2012; Zhang et al.,
2012).
Also, survival is the most important parameter reﬂecting
effects of CSC-targeting agent. However, previously studied CSC-
targeting agents did not show their survival beneﬁts in solid
cancers except for miR-34a (Liu et al., 2011; Visvader and Lin-
deman, 2012). But, only six mice and 13 days of observance after
treatment start in Liu’s study could not sufﬁciently show miR-
34a’s survival beneﬁts (Liu et al., 2011). By contrast, after 180 days’
observance, our study showed that 80% (8 of 10 mice) of 5%
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ethanol–DDP-treated mice were still alive while all 10 control mice
died before Day 123. The dramatic survival advantage in our study
indicates that targeting both SP cells and non-SP cancer cells in
the tumor by 5% ethanol–DDP has clear advantage over other
agents designed to speciﬁcally target ﬁxed population of CSC-like
cells.
High concentrations of ethanol (more than 95%) alone has
been successfully used in various types of tumor ablation especially
in liver tumor less than 3 cm during past 20 years (Ellman et al.,
1981; Livraghi et al., 1986; Kuang et al., 2009). Although high con-
centrations of ethanol can destroy various types of smaller tumors
than 3 cm through inducing tumor cells dehydration and necrosis,
proteins degeneration in larger tumor tissue induced by ethanol
can result in boundary formation, which impedes ethanol or toxic
agents to diffuse fully in the whole tumor and leads to some areas
unharmed (Lee et al., 1995). Also, higher concentration of ethanol
can cause severe damage to normal tissues like lung and intolera-
ble side effects to cancer patients, limiting its clinical applications
(Nair et al., 2008).
Studies by Pietronigro et al. (2003) showed that intratumoral
injection of chemotherapeutic agent BCNU dissolved in 100%
ethanol could produce a 40% cure rate in rats bearing intracranial
T9 tumors and 72% stable disease in recurrent malignant glioma
patients (Jenkinson et al., 2010). However, our unpublished data
showed chemotherapeutic agent DDP when dissolved in high con-
centration of ethanol such as 50% ethanol produced minimal
tumor inhibition associated with increased tumor angiogenesis
with obvious normal tissue damage compared with 5% ethanol–
DDP. This is consistent with Tan and Forsyth’s results that ethanol
could stimulate angiogenesis and promote tumor growth (Tan
et al., 2007; Forsyth et al., 2010). Together with boundary for-
mation effects and intolerable side effects of 100% ethanol, 5%
ethanol shows its superiority over high concentration of ethanol
as a solvent of cytotoxic chemotherapeutic agents such as cisplatin
or BCNU to destroy tumors.
Since ethanol and DDP are cheap and safe drugs available
in clinic for decades, local administration of them in mini-
mal dosage has clear advantage over other investigated CSC-
targeting agents on the bench to improve lung cancer survival in
clinic.
This study reports that 5% ethanol–DDP produced the most
potent in vivo effect among all reported CSC-targeting agents by
eradicating DDP-resistant lung tumors and extending survivals.
Since both ethanol and DDP have been used safely in clinic for
decades, image-guided intratumoral injectionor intrapleural infu-
sion of 5% ethanol–DDP to treat chemo resistant lung tumor or
malignant pleural effusion might provide a novel way to improve
lung cancer survival in clinic.
In conclusion, our studies showed that 5% ethanol decreased
ABCG2 protein function and 5% ethanol–DDP induced apoptosis
of lung SP cells plus non-SP cancer cells in vitro and DDP-
resistant lung tumor cells in vivo. Intratumoral injection of 5%
ethanol–DDP could eradicate DDP-resistant lung tumors and
extend survival, providing a novel approach to improve chemo
resistant lung cancer survival.
Clearly, clinical studies are needed to elucidate the efﬁcacy and
safety of this novel approach.
MATERIALS AND METHODS
ETHICS STATEMENT
Animal experiment was conducted with the approval of the
Institutional Animal Care and Use Committee of the China Agri-
cultural University. The conditions of the animals were monitored
daily for evidence of illness. Four steps were taken to minimize
the suffering of the animals as follow. Firstly, air exchange, tem-
perature, humidity, noise, light intensity, and light cycles were
maintained within limits compatible with the health and well-
being of the mice. Secondly, cleaning practices were monitored
on a regular basis to ensure effective hygiene and sterile sanita-
tion. Thirdly, to avoid unnecessary harm, drugs were injected
gently. Fourthly, mice showing severe distress including infection,
ulceration, cachexia, inability to ambulate, and moribund were
euthanized humanely in accordance with animal care protocol.
The euthanasia by cervical dislocation was used to sacriﬁce mice.
All mice were allowed to die after 180 days’ observance. Two mice
which showed severe distress because of biting infection in tumors
died for non-tumor-related reasons.
Some mice in this study suffered big tumors because the sur-
vival research requires an observance time as long as possible.
Meanwhile, we previously found that mice receiving ethanol
treatment showed larger tumors and better general conditions
compared with control mice. As a result, mice with larger tumors
still looked and livedwell in general conditions even 3weeks before
severe distress appeared.
CANCER CELL CULTURE AND REAGENTS
The cisplatin-resistant human lung adenocarcinoma cell line
A549/DDP was obtained from the American Type Culture Col-
lection (Rockville, MD, USA) and routinely cultured in RPMI
medium supplemented with 10% fetal bovine serum (Invitrogen
China Limited, Beijing, China) and 2 μmol cisplatin (Qilu Phar-
maceutical Co., Ltd., Shandong, China). A549/DDP cells were
cultured in complete RPMI medium without cisplatin for 3 days
before being used in experiments. >99.9% ethanol (vol/vol) was
bought from Sinopharm Chemical reagent Company (Beijing,
China). 5% ethanol (vol/vol) was prepared with >99.9% ethanol
and sterile water.
SIDE POPULATION SORTING AND ABCG2 FUNCTION ANALYSIS
A549/DDP cells were suspended at 1 × 106 cells/ml in phosphate
buffered saline solution (PBS) containing 4% FBS, incubated at
37◦C for 60 min with 5 μg/ml Hoechst 33342 (Sigma, St. Louis,
MO, USA) either alone or in the presence of 500 μmol verapamil
(Sigma, St. Louis, MO, USA). After incubation, 1 μg/ml pro-
pidium iodide was added and then the suspension was ﬁltered
through a 40 μm cell strainer (BD Bioscience, San Diego, CA,
USA) to obtain a single cell suspension. Flow cytometry analysis
and sorting were performed using a FACS Vantage SE (BD Bio-
science). Hoechst 33342 was excited with the UV laser at 350 nm
and ﬂuorescence emission was measured with 405/BP30 (Hoechst
blue) and 570/BP20 (Hoechst red) optical ﬁlters. A549/DDP cells
treated with 5% ethanol or control medium for 45 min were inves-
tigated for ABCG2 function by analyzing their Hoechst extrusion
properties and their sorting rates of SP cells were determined.
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QUANTITATIVE REAL-TIME RT-PCR
5% ethanol or control treated A549/DDP SP cells (for 2 h) and
tumor cells collected from 5% ethanol-treated or control mice
were suspended at 1 × 106 cells/ml in 5 ml PBS as sample respec-
tively. Then, isolation of total RNA was performed using RNeasy
Mini Kit (Qiagen, CA, USA) according to manufacturer’s instruc-
tions. The mRNA levels were analyzed by quantitative RT-PCR
using a Bio-Rad iCycler system (Bio-Rad, Hercules, CA, USA).
The mRNAs were reverse-transcribed into cDNAs by using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The
primer sequences and reaction conditions are same with those in
previous studies (Niu et al., 2012).
WESTERN BLOTS
Side population cells were treated with 5% ethanol or control
medium for 2 h and harvested for western blots analysis. Western
blots were carried out using the protocol published by Niu et al.
(2012). Primary antibody incubation was carried out at 4◦C for
16 h with a mouse anti-ABCG2 antibody (Biolegend, San Diego,
CA, USA) diluted at 1:300 in 3% bovine serum albumin, followed
by incubationwith horseradish peroxidase–conjugated horse anti-
mouse secondary antibody, and developed using an enhanced
chemiluminescence detection system (GE Healthcare, Piscataway,
NJ, USA). Anti–β-actin antibody was used as the loading control
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The densi-
ties of the protein bands in western blot were quantiﬁed with the
Quantity One-4.6.2 program (Bio-Rad, Berkeley, CA, USA).
ATPase ACTIVITY ASSAYS
1 × 106 SP cells were treated with 5% ethanol or control medium
for 2 h, and then thrice frost thawing was performed for cell dis-
ruption. The total protein was determinated by the method of
Bradford. The ATPase activities were assayed by the quantization
of phosphonium ions; the assay was performed in accordance
with the ATPase detection protocol developed by the Nanjing
Jiancheng Bioengineering Institute (Nanjing, China; Wang et al.,
2008). The reaction product was tested by 721-spectrophotometer
at the wavelength of 660 nm. ATPase activity of A549 SP cells
(μmol Pi/mg protein/h) were calculated as the quantity of Pi
(μmol), which decomposed from ATP by 1 mg ATPase in 1 h.
TRANSMISSION ELECTRON MICROSCOPY
For TEM, 1 × 106 SP cells were treated with 5% ethanol or con-
trol medium for 2 h and then were ﬁxed for 3 h with buffered
1% parahormaldehyde–1.25% glutaraldehyde, osmicated, dehy-
drated, and embedded in Epon. Slips were examined by transmis-
sion electron microscopy JEM-2010 (JEOL, Tokyo, Japan) and FEI
Tecnai 20 (FEI, Eindhoven, Netherlands).
APOPTOSIS ASSAYS BY FLOW CYTOMETRY
2 × 106 A549/DDP SP cells or 2 × 106normal A549/DDP cells
were treated with 5% ethanol, 5% ethanol plus 2.2 μg/ml cis-
platin (DDP), DDP, and control for 2 h and then stained using the
Annexin V-FITC apoptosis detection kit (BioVision, Mountain
View, CA, USA) and analyzed on a FACScalibur ﬂow cytometer
(BD Bioscience).
TUNEL APOPTOSIS ASSAYS OF TUMOR TISSUES
Brieﬂy, dewaxed tissue sections were predigested with 20 mg/ml
proteinase K for 20 min and incubated in PBS containing 3%
H2O2 for 10min toblock the endogenousperoxidase activity. After
blocking endogenous peroxidases, tissue sections were incubated
in equilibration buffer and treated with terminal deoxynucleotidyl
transferase (TdT) enzyme to detect TUNEL-positive nuclei
according to the manufacturer’s guide (Roche Scientiﬁc, Indi-
anapolis, IN, USA). Tissues were then incubated with converter-
POD (Roche Scientiﬁc, Indianapolis, IN, USA) and color devel-
oped with diaminobenzidine (DAB; Sigma-Aldrich, Munich,
Germany). After counterstaining with methyl green, sections were
protected with cover slip and secured with mounting medium.
Positive control sections were incubated with 5 μg/ml DNase
(Sigma-Aldrich, Munich, Germany) for 10 min at 37◦C to induce
DNA strand breaks. Negative control sections were obtained by
omitting the TdT enzyme from the TdT reaction buffer.
TUMOR GROWTH XENOGRAFT STUDY
Six-week-old inbred male Balb/C nude mice were obtained from
the Institute of ChineseAssociation for LaboratoryAnimal Science
(CALAS, Beijing, China). A549/DDP lung adenocarcinoma cells
(5 × 106) were subcutaneously inoculated in the upper left ﬂank
on day 1. When the diameters of tumors were >5 mm, the mice
were divided into control, 5% ethanol, DDP, 5% ethanol + DDP
(n = 10 each). Mice in each group were treated with intra-tumoral
injection of 150 μl of sterile water, or 5% ethanol, or 8 mg/kg
DDP in sterile water, or 5% ethanol + 8 mg/kg DDP accordingly
twice a week for 4 weeks. All solutions used sterile water as sol-
vent. Tumor volume was determined with caliper and calculated
using (width2 × length)/2 twice a week. Survivals of mice in each
group were observed and recorded (Niu et al., 2012). To minimize
the suffering of the animals, cleaning practices were monitored
on a regular basis to ensure effective hygiene and sterile sanita-
tion. To avoid unnecessary harm, drugs were injected gently. The
conditions of the animals were monitored daily for evidence of ill-
ness. Mice showing severe distress including infection, ulceration,
cachexia, inability to ambulate and moribund were euthanized in
accordance with animal care protocol. All mice were allowed to
die after 180 days’ observance.
STATISTICAL ANALYSIS
Data are presented as mean ± SD except for survival analysis
as mean ± SE. Paired and unpaired student’s t-test was used to
analyzing two groups of paired or unpaired data, respectively.
Repeated measured analysis of variance (ANOVA) was used for
comparison of multiple groups. Survival analysis was calculated
according to the Kaplan–Meier method and log-rank (mantel–
cox) test with SPSS software (IBM, Armonk, NY, US). Mice alive
at the end of the study were censored. Differences were considered
signiﬁcant at p < 0.05.
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